Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Traws Pharma Inc TRAW

Healthcare
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a... see more

Recent & Breaking News (NDAQ:TRAW)

Onconova Therapeutics, Inc. [ONTX] to Ring The NASDAQ Stock Market Closing Bell

Globe Newswire December 16, 2013

Onconova Therapeutics to Host Analyst Event in New York City on December 19th

Globe Newswire December 13, 2013

Onconova Announces Presentation of Positive Data From Clinical Trials of Rigosertib in Myelodysplastic Syndromes (MDS) at the 2013 ASH Annual Meeting

Globe Newswire December 9, 2013

Onconova Therapeutics, Inc. to Present at the 25th Annual Piper Jaffray Healthcare Conference

Globe Newswire November 27, 2013

Onconova Therapeutics, Inc. Reports Third Quarter 2013 Financial and Operational Results

Globe Newswire November 12, 2013

Onconova Announces Presentation of Rigosertib Clinical Data in Myelodysplastic Syndromes (MDS) at the 2013 ASH Annual Meeting

Globe Newswire November 7, 2013

Onconova Therapeutics, Inc. Announces Timing for Third Quarter 2013 Financial Results and Conference Call

Globe Newswire November 5, 2013

Onconova Therapeutics, Inc. Reports Second Quarter 2013 Financial and Operational Results

Globe Newswire September 6, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on AGIO, EPZM, ONTX and XON

Accesswire August 26, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on AGIO, HUN, KALU and ONTX

Accesswire August 20, 2013

Onconova Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option

Globe Newswire July 30, 2013

Onconova Appoints Dr. Jerome Groopman and Anne VanLent to Board of Directors

Business Wire July 29, 2013